Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication
- 28 July 2025
- journal article
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (12) , 2317-2323
Abstract
Background: Foslevodopa/foscarbidopa (LDp/CDp) significantly reduced motor fluctuations in people with Parkinson's disease (PwP) in clinical trials, but its real‐world tolerability and optimal dosing remain unclear. Objectives: To assess tolerability, dosing patterns, and modifications to concomitant medication with LDp/CDp in clinical practice. Methods: A single‐center retrospective cross‐sectional analysis. Results: The LDp/CDp was initiated in 53 PwP (41% women, mean age 66 ± 11.3 years, mean disease duration 14.1 ± 5.7 years, median H&Y 4 (3–5); history of cognitive impairment: 40%, history of psychosis: 62%, previous device aided therapies failure: 39%). After an optimization period (18.4 ± 6.8 days), the mean Base hourly infusion rate was significantly higher than recommended (0.39 ± 0.18 vs. 0.32 ± 0.13 ml/h, p < 0.001) and the LDp/CDp was co‐administered with MAO‐B‐inhibitors (50%), COMT‐inhibitors (44%), and dopamine agonists (12%). Adverse events occurred in 40%: skin reactions (31%), psychosis (8%), falls (2%), and nausea (2%). Thirteen patients discontinued therapy. Conclusions: LDp/CDp may be an effective and well‐tolerated non‐surgical option for managing motor fluctuations in PD, though higher dosing and combination therapy are often required.Keywords
This publication has 26 references indexed in Scilit:
- Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's DiseaseMovement Disorders Clinical Practice, 2025
- Update on Treatments for Parkinson's Disease Motor Fluctuations – An International Parkinson and Movement Disorder Society Evidence‐Based Medicine ReviewMovement Disorders, 2025
- Neutrophil‐Rich Infusion Site Reactions After Continuous Subcutaneous Application of Foslevodopa/FoscarbidopaMovement Disorders, 2025
- Skin Inflammatory Reactions in Patients with Continuous Subcutaneous Injection of Foslevodopa‐Foscarbidopa Hydrate: HistopathologyMovement Disorders, 2024
- Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and ProposalsMovement Disorders, 2023
- European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive TherapiesMovement Disorders, 2022
- Movement Disorder Society–Unified Parkinson's Disease Rating Scale Use in the Covid‐19 EraMovement Disorders, 2020
- Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging FeaturesMovement Disorders, 2018
- Parkinson's disease symptoms: The patient's perspectiveMovement Disorders, 2010
- International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest studyMovement Disorders, 2006